
SNNA
Other · Other · $4.2M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2019
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 14, 2019 | Time not confirmed | -0.83 | -0.93 | -12.0% |
| Nov 8, 2018 | Time not confirmed | -0.79 | -0.82 | -3.8% |
| Aug 9, 2018 | Time not confirmed | -0.79 | -1.00 | -26.3% |
| May 14, 2018 | Time not confirmed | -0.71 | -0.85 | -19.1% |
| Mar 15, 2018 | Time not confirmed | -0.80 | -0.56 | +30.0% |
Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the…